БЛОКАТОРЫ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II И НЕФРОПРОТЕКЦИЯ: ПОЗИЦИИ ОЛМЕСАРТАНА
https://doi.org/10.15829/1728-8800-2013-4-82-85
Аннотация
Обсуждаются результаты экспериментальных и контролируемых клинических исследований, демонстрирующих нефропротективный эффект олмесартана.
Об авторе
В. В. Фомин
ГБОУ ВПО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России, Москва
Россия
Россия
д. м.н., профессор, декан лечебного факультета, профессор кафедры терапии и профболезней медико-профилактического факультета
Список литературы
1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
2. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
3. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction wit VALsartan Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672–6.
4. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
5. Makino H, Haneda M, Babazono T et al.; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30 (6): 1577–8.
6. Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs of Today 2003; 39 (19): 745–61.
7. Ideura H, Hiromura K, Hiramatsu N, et al. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol 2007; 293 (4): F1214–21.
8. Mima A, Matsubara T, Arai H, et al. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Invest 2006; 86 (9): 927–39.
9. Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010; 28 (11): 2289–98.
10. Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012; 25 (5): 604–11.
11. Haller H, Ito S, Izzo JL, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
12. Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
13. FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events. http: www.fda.gov.
14. Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
15. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–7.
16. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1–10.
17. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
18. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11–20.
19. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49–57.
20. Januszewicz A, Ritz E, Viberti G, et al. Office and ambulatory pulse pressure association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). J Hum Hypertens 2011; 25 (11): 679–85.
21. Menne J, Izzo JL Jr, Ito S, et al.; ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30 (4): 811–8.
22. Malacco E, Omboni S, Mallion JM, Volpe M; ESPORT Study Group. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status: a retrospective analysis. High Blood Press Cardiovasc Prev 2012; 19 (4): 213–22.
23. Nishida Y, Takahashi Y, Nakayama T, et al. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011; 10: 74.
24. Koc Y, Mazi E, Sakaci T, et al. Effect of olmesartan on serum cystatin C levels in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1389–94.
Рецензия
Для цитирования:
Фомин В.В. БЛОКАТОРЫ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II И НЕФРОПРОТЕКЦИЯ: ПОЗИЦИИ ОЛМЕСАРТАНА. Кардиоваскулярная терапия и профилактика. 2013;12(4):82-85. https://doi.org/10.15829/1728-8800-2013-4-82-85
For citation:
Fomin V.V. ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN. Cardiovascular Therapy and Prevention. 2013;12(4):82-85. (In Russ.) https://doi.org/10.15829/1728-8800-2013-4-82-85
Просмотров:
769
Послать статью по эл. почте 
